{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T23:41:49Z","timestamp":1772926909337,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00824","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T06:22:24Z","timestamp":1766125344000},"page":"e00824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Switching high efficacy therapies in Multiple Sclerosis: Does real world experience support such a strategy?"],"prefix":"10.1016","volume":"23","author":[{"given":"Suhayl","family":"Dhib-Jalbut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.neurot.2025.e00824_bib1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/CON.0000000000001170","article-title":"Treatment of multiple sclerosis","volume":"28","author":"Cross","year":"2022","journal-title":"Continuum"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00824_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00415-025-13330-7","article-title":"Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis","volume":"272","author":"Ellenberger","year":"2025","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00824_bib3","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s40120-025-00754-6","article-title":"Disease course in patients switched from natalizumab to alemtuzumab: an Italian multicenter, prospective, observational study","volume":"14","author":"Malucchi","year":"2025","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2025.e00824_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106564","article-title":"Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study","volume":"101","author":"Cunha","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00824_bib5","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00415-025-13283-x","article-title":"Clinical outcomes after switching from fingolimod to B-cell-depleting therapies in multiple sclerosis: systematic review and meta-analysis","volume":"272","author":"de Souza Wagner","year":"2025","journal-title":"J Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2025.e00824_bib6","article-title":"Transition from anti-CD20 therapies to fumarates as a treatment strategy: a multicenter, retrospective observational experience","volume":"11","author":"Vollmer","year":"2025","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00824_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00724","article-title":"Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: insights from naive and switch patients","volume":"22","author":"Chisari","year":"2025","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00824_bib8","first-page":"e00812","article-title":"Switching from anti-CD20 therapies to cladribine and vice versa \u2013 analysis of a German relapsing multiple sclerosis cohort","volume":"23","author":"Konen","year":"2026","journal-title":"Neurotherapeutics"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00824_bib9","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1177\/13524585251361330","article-title":"Disease outcomes following lateral switch among different CD20-antibodies in active multiple sclerosis","volume":"31","author":"Axhausen","year":"2025","journal-title":"Mult Scler"},{"issue":"suppl 1","key":"10.1016\/j.neurot.2025.e00824_bib10","first-page":"629","article-title":"Treatment patterns prior to and post cladribine in patients with multiple sclerosis","volume":"29","author":"Ellenberger","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurot.2025.e00824_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2025.1635618","article-title":"Predictors of therapy switching to high-efficacy disease-modifying therapies in patients with multiple sclerosis: a single center, retrospective, observational study","volume":"16","author":"Makarevicius","year":"2025","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00824_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00734","article-title":"Two roads diverged in multiple sclerosis: when is switching therapy effective?","volume":"22","author":"Reder","year":"2025","journal-title":"Neurotherapeutics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925003022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925003022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:01:07Z","timestamp":1772856067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925003022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925003022"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00824","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching high efficacy therapies in Multiple Sclerosis: Does real world experience support such a strategy?","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00812","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00824"}}